What Palatin Technologies (PTN) Said on Its Q1 Earnings Call

Palatin Technologies (NYSEAMERICAN:PTN) is preparing to move its lead obesity drug candidate into human testing in the first half of 2027 while seeking additional capital to fund its development plans, executives said on the company’s fiscal first-quarter earnings call.

The company reported a $5.1 million net loss for the quarter ended Sept. 30, 2026, as research spending rose and collaboration revenue declined from a year-earlier period that included substantial payments from its Boehringer Ingelheim agreement. Palatin ended the quarter with $3.7 million in cash and cash equivalents.

Obesity programs approach clinical testing

Palatin’s lead candidate is a long-acting, lipidated peptide from its PL2000 series that targets the melanocortin-4 receptor, or MC4R. The company is developing MC4R agonists for rare neuroendocrine obesity disorders and aims to improve tolerability and dosing convenience while minimizing skin darkening associated with activation of a separate receptor, MC1R.

CEO and President Carl Spana said tested compounds from Palatin’s two next-generation peptide series showed MC4R agonist activity without acting as agonists at MC1R. The lead PL2000 candidate reduced food intake and body weight in diet-induced obese mice after weekly injections, he said. Pharmacokinetic findings in larger animals supported the potential for weekly or less frequent dosing in humans.

The planned phase 1 study will assess safety, tolerability, pharmacokinetics and pharmacodynamics, as well as skin pigmentation, weight, body mass index and appetite. Palatin is targeting initial clinical data in the second half of 2027.

Spana said the majority of non-animal toxicology studies had been completed and that Palatin was preparing to begin 28-day studies in rats and dogs. Those studies are the main remaining gating item before filing, alongside manufacturing and documentation work, he said. The company expects the requirements to be in place for a filing in the second quarter of 2027.

While Palatin expects its selectivity approach to reduce or eliminate hyperpigmentation, Spana acknowledged that the effect will not be known until clinical testing. He said animal models for predicting hyperpigmentation are not well validated.

Palatin is also advancing an oral small-molecule program, with candidate selection and IND-enabling development targeted for the first half of 2027 and a phase 1 start planned for the second half. During the question-and-answer session, CFO and COO Steve Wills said the oral small-molecule and oral peptide programs were tracking about two quarters behind the lead peptide, with data expected in the first half of 2028.

The company is continuing work on its non-lipidated PL1000 peptide series and an earlier-stage oral peptide approach. Spana confirmed that PL2000 is expected to enter the clinic before PL1000.

Spending rises as revenue falls

Quarterly collaboration and license revenue fell to approximately $362,000 from $8.8 million a year earlier. Wills said the latest revenue came from research and development services under the Boehringer Ingelheim collaboration, while the prior-year figure included substantial upfront milestone payments associated with the agreement.

Research and development expenses increased to $3.4 million from $2.5 million. Spending directly related to MC4R obesity programs rose to approximately $2.1 million from $1 million as Palatin advanced studies for the long-acting peptide and optimized oral small-molecule candidates. General and administrative expenses increased to $2.1 million from $1.7 million, primarily because of higher stock-based compensation and professional fees.

The net loss was $1.29 per basic and diluted share. Net cash used in operating activities increased to $3.7 million from $1.6 million a year earlier.

Capital and partnerships remain priorities

Wills said Palatin needs additional capital for the next stages of development and is evaluating public and private equity transactions, strategic collaborations and other opportunities. He said interest in the company had increased significantly in recent months, driven primarily by the MC4R landscape, but cautioned that Palatin could not assure the timing or terms of a transaction.

As phase 1 studies approach, expenses associated with manufacturing, toxicology, regulatory work and trial preparation are likely to rise, Wills said. He added that the company has flexibility in managing the timing and pace of spending.

Outside its internally funded obesity programs, Palatin’s retinal disease collaboration with Boehringer Ingelheim provides research reimbursement and potential milestone payments and royalties, Spana said. Its agreement with Altanispac Labs transfers future development responsibility for PL9643 in dry eye disease while preserving potential future economics for Palatin.

Asked whether future Boehringer payments might offset financing needs, Wills declined to specify anticipated milestones or their timing, citing competitive and confidentiality reasons. He said Palatin had received approximately $10 million from the collaboration since August 2025 and that the program was progressing.

About Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, which are involved in processes such as inflammation, immune response and appetite regulation. Its research has included peptide-based treatments for inflammatory and other medical conditions. The company is best known for developing bremelanotide, marketed as Vyleesi, which the U.S. Food and Drug Administration approved in 2019 to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.